Invitae Hereditary Renal/Urinary Tract Cancers Panel
Use
The Invitae Hereditary Renal/Urinary Tract Cancers Panel is designed to analyze genes associated with predisposition to cancers of the kidneys and urinary tract. Given the clinical overlap of renal and urinary tract cancer susceptibility conditions, this panel allows for an efficient evaluation of multiple potential genes based on a single clinical indication. Genetic testing can confirm a clinical diagnosis, predict disease prognosis, facilitate early detection, inform family planning, and support enrollment in clinical trials. The test specifically targets heritable germline mutations and is not appropriate for detecting somatic mutations in tumor tissue.
Special Instructions
The panel allows customization by adding or removing genes according to the clinical case needs. Specimen collection kits are available upon request. Given the genetic heterogeneity of hereditary cancer syndromes, covering an extensive set of genes helps to address the clinical complexities and inform clinical decision-making.
Limitations
This test may not detect all types of genetic variants. Structural variants like inversions, gene conversion events, and complex sequence architectures may not be identified. Some single-exon deletion events may escape detection due to inherent sequence properties or isolated data quality issues. Variants in promoter, non-coding exons, and other non-coding regions are generally not analyzed unless explicitly covered. Assessment of mosaicism, phasing, and mapping ambiguities may not be fully resolved. Sensitivity for insertion/deletion mutations larger than 15bp but smaller than a full exon may be reduced.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
Purple-top EDTA tube (K2EDTA or K3EDTA)